Close
Smartlab Europe
Inizio Ignite

Business & Industry

Kindeva Announces the Appointment of David Stevens as President

Kindeva, a global contract development and manufacturing organization (CDMO) and drug delivery innovator, announced the promotion of David Stevens, Chief Operating and Commercial Officer, to the newly created role of President. In this capacity, David will lead Kindeva’s global...

J&J To Be in Sync with Trump Administration as MFN Spreads

As the two Trump administration drug pricing deals find their place in the books and more that are likely on the way, the U.S. policy environment can very well soon stabilize for many Big Pharma companies. All this puts...

Investments in the U.S. of Over $70bn Announced by Merck

It is well to be noted that in 2025, a minimum of 14 major pharmaceutical companies across the world went ahead and announced plans to broaden their manufacturing presence in the U.S. so as to lessen the supply chain...

US Tariffs on Pharma Exports from Singapore Deferred

As originally reported by the Straits Times and also shared by Reuters, the enforcement of US tariffs on pharma exports from Singapore is being deferred so as to provide stakeholders ample time to work out an amicable deal with the US...

Nabla & Takeda Expand Partnership on AI In Drug Development

Nabla Bio, the U.S. biotech firm, said on October 14, 2025, that it has signed a second major research partnership along with Takeda Pharmaceutical, the Japanese drugmaker, thereby deepening their usage of AI in drug development. As per the new...

AstraZeneca Plant Expansion to Double Production of Lokelma

AstraZeneca has gone on to announce a newly expanded manufacturing facility located in Coppell, Texas, U.S., which is going to double production of Lokelma for the advantages of patients across the U.S. as well as around the world. This $445 million...

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression to phase 2 clinical trials in Malawi. Demonstrates Recipharm’s agility and flexibility, completing full tech transfer, scale-up and process optimisation within three months. Strengthens Recipharm’s position as a trusted partner...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »